10th IAS Conference on HIV Science

Download All
July 21-24, 2019; Mexico City, Mexico
CCO is the official provider of online scientific analysis for the 2019 International AIDS Society meeting through Capsule Summaries, downloadable slides, rapid expert Webinars, and ClinicalThought commentaries.


Capsule Summaries

First-line raltegravir 400 mg BID achieved HIV-1 RNA < 50 copies/mL in 61% of patients vs 66% with efavirenz 600 mg QD, each combined with 3TC/TDF in HIV/TB-coinfected patients receiving rifampin.

Released: July 23, 2019

Virologic suppression rates and CD4+ cell counts continued to improve through Week 96 in this difficult-to-treat population receiving fostemsavir plus optimized background therapy.

Released: July 24, 2019

97% of patients receiving long-acting injectable therapy said that they preferred it to continued daily oral ART.

Released: July 25, 2019

93% of switched patients maintained virologic suppression in study population that included patients with preexisting NRTI, NNRTI, or PI resistance.

Released: July 26, 2019

In updated birth outcomes surveillance analysis, NTD prevalence slightly higher with DTG vs non-DTG ART (0.3% vs 0.1%; estimated difference: 0.20% to 0.27%).

Released: July 24, 2019

Differences in pharmacokinetics may account for the trend toward lower HIV infection rates with FTC/TAF vs FTC/TDF as PrEP in MSM and transgender women enrolled on the phase III DISCOVER trial.

Released: July 26, 2019

Virologic suppression maintained in patients who initiated triple therapy with islatravir + DOR + 3TC, achieved virologic suppression, and then switched to 2-drug therapy with islatravir + DOR.

Released: July 29, 2019

In phase III study, switch to this dual therapy noninferior to continuing TAF-based triple therapy.

Released: July 26, 2019

In prespecified secondary analyses, HIV-1 RNA < 50 copies/mL achieved by 86.0% of patients receiving dual therapy vs 89.5% receiving triple-drug ART.

Released: July 24, 2019

Phase III trial supports use of DTG-based regimens, with low rates of emergent resistance and no INSTI resistance.

Released: July 29, 2019
Provided by USF

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
IAS 2019 Media Partner Logo
Educational grant provided by:
Gilead Sciences
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings